News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Phase I
Inergetics, Inc. Completes Phase I Development Of Its Therapeutic CBD Line Of Products 7/29/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Galectin Therapeutics To Host Webcast To Discuss Findings From Cohort 2 Of Phase 1 Clinical Trial Of GR-MD-02 In Fatty Liver Disease With Advanced Fibrosis 7/25/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer 7/24/2014
Advanced Biologics Publishes Additional Osteoamp® Abstracts In The Bone And Joint Journal 7/24/2014
Media Advisory: AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine 7/24/2014
Amunix, Inc. And PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates In Vivo Studies In American Chemical Society's Journal 7/24/2014
Biosceptre Announces Positive Phase I Results For BIL-010t To Treat Basal Cell Carcinoma 7/23/2014
Dyax Corp. (DYAX) Announces Publication Of Scientific Data For DX-2930 In Peer-Reviewed Journals 7/23/2014
Ligand Pharmaceuticals Inc. (LGND) Partner SAGE Therapeutics Receives Fast Track Designation For Captisol-enabled SAGE-547 To Treat Status Epilepticus 7/23/2014
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
MYOS (MYOS) Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects 7/22/2014
Jazz Pharmaceuticals plc (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide A Phase 1 Clinical Trial Update On JZP-386 7/22/2014
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of Phase 1B Clinical Trial Of GR-MD-02 In Combination With Ipilimumab In Metastatic Melanoma 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Regulus Therapeutics, Inc. Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome 7/21/2014
Ignyta (RXDX) Announces Initiation Of STARTRK-1 Global Phase I/II Clinical Trial Of RXDX-101 7/21/2014
Synthetic Biologics, Inc. (SYN)' Academic Collaborator To Present Novel Monoclonal Antibody Combination For Treating Whooping Cough (Pertussis) At Gordon Research Conference 7/21/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update on TKM-Ebola Phase I Clinical Hold 7/21/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update On TKM-Ebola Phase I Clinical Hold 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
Rexahn Pharmaceuticals, Inc. (RNN) Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors 7/18/2014
FDA Lifts Partial Clinical Hold For Concert Pharmaceuticals, Inc. (CNCE)'s CTP-354 7/17/2014
Nuvilex (NVLX) And Austrianova Announce Results Of Clinical Trial In Dogs With Mammary Tumors Treated With Cell-In-A-Box® Plus Cyclophosphamide 7/17/2014
Silk Road Medical Completes Enrollment In The ROADSTER Clinical Trial For Carotid Artery Disease 7/17/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 7/17/2014
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion Of Phase 1 Skin Irritation Trial Of Locilex® 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Capricor Therapeutics, Inc. Announces Encouraging Results From Phase1 ALLSTAR Trial; Phase 2 Trial Underway 7/16/2014
Northwest Biotherapeutics (NWBO) Announces Completion Of DCVax®-Direct Phase I Trial Recruitment 7/16/2014
BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment 7/16/2014
ChromaDex, Inc. Initiates First Human Clinical Study To Confirm ChromaDex's NIAGEN™ Nicotinamide Riboside Will Increase NAD+ 7/16/2014
ImQuest Pharmaceuticals, Inc. Receives FDA Approval To Initiate Clinical Trials Of A Vaginal Gel For The Prevention Of HIV Transmission To Women 7/16/2014
Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical And Chemical Manipulation 7/15/2014
Cellceutix (CTIX) Announces Breakthrough In The Formulation Of Its Novel Antibiotic Brilacidin™, Plans Studies To Treat Diabetic Foot Ulcers 7/15/2014
Helix Biopharma (CC:HBP) Initiates Enrollment For Ninth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 7/15/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
QLT Inc. (QLTI) Announces Publication In The Lancet Of Phase 1b Data For QLT091001 In Leber Congenital Amaurosis Due To LRAT Or RPE65 Mutations 7/14/2014
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Uremic Pruritus 7/14/2014
Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease 7/10/2014
Dezima Pharma Extends Clinical Development Program For Its CETP Inhibitor TA-8995 7/9/2014
Soligenix (SNGX) Announces Combination Vaccine For Ricin And Anthrax Achieves Simultaneous Protection 7/9/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Initiation Of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma 7/9/2014
Novartis AG (NVS) Wins Breakthrough Status For New Leukemia Treatment CTL019 7/8/2014
Cesca Therapeutics Management Provides Regulatory Update On Its Proposed U.S. Pivotal Critical Limb Ischemia Clinical Trial 7/8/2014
Cortice Biosciences Announces Enrollment Of A Phase 1 Clinical Trial Evaluating TPI 287 In Rare Tauopathy Diseases 7/7/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
Reaction Biology Corp. Receives National Institutes of Health (NIH) Grant Award For Epigenetic Database 7/7/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-290 7/7/2014
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 For Treatment Of Autoimmune Diseases Entering Human Trials 7/3/2014
Akashi Therapeutics Presents Positive Clinical Data On HT-100 In Patients With Duchenne Muscular Dystrophy 7/3/2014
Akashi Therapeutics Receives Fast Track Designation For HT-100 From FDA For The Treatment Of Duchenne Muscular Dystrophy 7/3/2014
Tekmira Pharmaceuticals Corporation (TKMR) Sinks As The FDA Puts Ebola Study On Hold; Stock Down -15.54% At Market Close (July 3, 2014) 7/3/2014
Galapagos NV (GLPG.BR) Initiates Phase 1 Study With GLPG1690, Triggering €6.6 M Milestone In The Alliance With Janssen Pharmaceutica N.V. 7/1/2014
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014
Genocea Biosciences Announces Positive Top-Line 12-Month Follow-Up Data From Phase 1/2a Clinical Trial For HSV-2 Immunotherapy GEN-003 7/1/2014
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Additional Data Demonstrating Efficacy Of AEOL 10150 As A Medical Countermeasure Against Exposure To Nerve Agents, Sulfur Mustard Gas And Nitrogen Mustard Gas 7/1/2014
CritiTech Announces Positive Results From Phase I Trial Of Nanotax® For Intraperitoneal Cancers 7/1/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Nora Therapeutics Presents Phase 1 Data On NT100 At The European Society Of Human Reproduction And Embryology Annual Meeting 6/30/2014
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial Of Erepoxen® 6/30/2014
Anavex Life Sciences Corp. (AVXL.OB) Announces Report Expanding Opportunity For Therapeutic Application Of Anavex Compounds 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
First Patient Enrolled In FDA Phase 1/2a Clinical Trial With Biolight's Controlled-Release Latanoprost Insert For The Treatment Of Glaucoma 6/30/2014
Retrophin, Inc. (RTRX) Slumps As Patient On Key Drug Shows High Liver Enzyme Levels 6/27/2014
Antibe Therapeutics Inc. Announces First Human Dose Of ATB-346 In Phase I Clinical Trial 6/27/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation 6/26/2014
Targacept, Inc. (TRGT) Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis 6/25/2014
Calimmune Approved To Treat Second Group In HIV Stem Cell Gene Modification Study 6/25/2014
Debiopharm And TCG Lifesciences Announce Successful Completion Of First Phase Of Research Collaboration On Discovery Of Novel Antibiotics 6/24/2014
Results Of Phase 1b Clinical Trial Comparing Trevena, Inc. (TRVN)’s TRV130 To Morphine Published In The Journal Pain 6/24/2014
Ultragenyx Pharmaceuticals Announces Results From Phase 1/2 Study Of KRN23 In X-Linked Hypophosphatemia In Adults 6/24/2014
Regado Biosciences, Inc. (RGDO)' REG2 Demonstrates Dose And Concentration-Dependent Suppression Of Thrombin Generation 6/23/2014
Ligand Pharmaceuticals Inc. (LGND) Announces Presentation Of Positive Data From A Phase 1 Study On The Effect Of The SERM Lasofoxifene To Increase Testosterone Levels In Men 6/23/2014
Trevena, Inc. (TRVN) Announces Positive Phase 1 Results For TRV734 For Acute And Chronic Pain 6/23/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER2 Study 6/23/2014
Triphase Accelerator Announces Orphan Drug Designation In The European Union For Marizomib For Multiple Myeloma 6/23/2014
Enteris Biopharma Oral Peptide Delivery Technology Enables Key Clinical Milestone For Acute And Chronic Pain Drug 6/20/2014
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014
StemCells Inc. (STEM) Announces Closure Of Enrollment In Phase 1/2 Dry Age-Related Macular Degeneration Trial 6/20/2014
NeoStem, Inc. Announces University of California, San Francisco (UCSF) Presentation Of Phase 1 Results For T Regulatory Cell Immunotherapy For Type 1 Diabetes At American Diabetes Association Annual Meeting 6/19/2014
Aratana Therapeutics (PETX) Initiates And Doses First Patient In Market Development Studies Of AT-005 For Treating Canine T-Cell Lymphoma 6/19/2014
NeuralStem Inc. NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress 6/19/2014
StemCells Inc. (STEM) Interim Results Show Improvement In Visual Function And Slowing Of Disease Progression In Phase 1/2 Dry AMD Trial 6/19/2014
MacroGenics, Inc. (MGNX) Initiates Phase 1 Study Of MGD006 For The Treatment Of Acute Myeloid Leukemia 6/19/2014
GlycoMimetics, Inc. (GLYC) Initiates First Clinical Trial Of GMI-1271 As Potential Treatment For Blood-Related Cancers 6/19/2014
Enrollment Continues Into Bio-Path Holdings, Inc. (BPTH) Phase I Clinical Trial 6/19/2014
Antibe Therapeutics Inc. Receives Approval From Health Canada To Begin Human Clinical Testing 6/19/2014
OncoMed Pharmaceuticals, Inc. (OMED) Provides Update on FZD8-Fc (OMP-54F28) Phase I Clinical Trials 6/19/2014
Cara Therapeutics, Inc. (CARA) Initiates Phase 1a/1b Trial Of Tablet Formulation Of Oral CR845 For The Treatment Of Acute And Chronic Pain 6/18/2014
Gradalis Inc. Announces Presentation Of New Data 6/18/2014
Asmacure Announces Top-Line Clinical Results For ASM-024 DPI In Ph 1/2a Trial 6/18/2014
NeuralStem Inc. Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting 6/18/2014
FutureCeuticals Release: Human Clinical Study Further Indicates FruiteX-B® Calcium Fructoborate Provides Fast-Acting Joint And Flex Benefits 6/17/2014
FDA Release: DNAtrix, Inc. Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma 6/17/2014
Cambridge-Based bluebird bio (BLUE)'s Gene Therapy Quickly Halts Blood Disease In Small Study; Stock Up 32.08% At Market Close (June 16, 2014) 6/17/2014
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Voluntarily Halts Early-Stage Trials for Two Cancer Drugs 6/16/2014
Advaxis, Inc. Evaluates Higher Dose And Repeat Cycles Of ADXS-HPV In Phase 1/2 Cervical Cancer Trial 6/16/2014
Ligand Pharmaceuticals Inc. (LGND) Announces Successful First-In-Human Trial Results For Glucagon Program 6/16/2014
Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-221 For Treatment Of Acute Myelogenous Leukemia 6/16/2014
Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 6/16/2014
Boston Biomedical Announces Clinical Data Presentation Of Its Cancer Stem Cell Inhibitor Programs 6/16/2014
Islet Sciences Presents Positive Clinical Results For Best-In-Class SGLT2 Inhibitor At American Diabetes Association Annual Meeting 6/16/2014
BioLineRx Ltd. Receives Approval To Commence Phase 1 Trial For Novel Stem Cell Mobilization Treatment 6/16/2014
New Agios Pharmaceuticals (AGIO) Clinical Data From Ongoing Phase 1 Trial Of AG-221 Continue To Show Complete And Durable Remissions In Patients With Difficult To Treat Hematologic Malignancies 6/16/2014
Fibrocell Science, Inc. Receives Orphan Drug Designation For Genetically-Modified Autologous Human Fibroblasts To Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB) 6/13/2014
Protalex, Inc. (PRTX) Announces Data from U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients Presented At The 2014 EULAR Annual European Congress of Rheumatology 6/13/2014
Karyopharm Therapeutics (KPTI) Announces First Combination Data Of Selinexor With Low-Dose Dexamethasone In Heavily Pretreated Multiple Myeloma Patients 6/13/2014
Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) Is Active And Well-Tolerated In Ongoing Phase 1b Studies In Patients With Refractory Multiple Myeloma At The 19th Congress Of The European Hematology Association 6/13/2014
Geron Corporation (GERN) Jumps As FDA Lifts Partial Hold On Myelofibrosis IST 6/12/2014
Diagram Release: First Patient Enrolled In Investigator Initiated REDUCE Study 6/12/2014
Ruthigen Cleared To Initiate Human Clinical Trials For RUT58-60 In The U.S. 6/12/2014
Capstone Therapeutics (CAPS) Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects 6/12/2014
Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem 6/12/2014
Interim Results Of First Clinical Trial Of Themis Bioscience’s Vaccine Candidate Against Chikungunya Fever Prove Successful 6/12/2014
Marina Biotech, Inc. (MRNA) Announces That Licensee Mirna Therapeutics, Inc. Enrolls First Patient In Hematologic Malignancy Cohort Of On-Going Trial 6/12/2014
Oncobiologics Inc. Launches Phase I Clinical Trial For ONS-3010 Biosimilar Version Of Humira® 6/12/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX-Direct Trial Update Indicates Further Positive Responses; 3 Case Studies Show No Live Tumor Cells In Injected Tumors 6/11/2014
Capstone Therapeutics Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects 6/11/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014) 6/11/2014
Inovio Pharmaceuticals (INO) Initiates Immune Therapy Trial For Head & Neck Cancer Caused By HPV 6/10/2014
Mirna Therapeutics, Inc.Announces First Patient Enrolled In Hematological Malignancy Cohort Of Its Phase 1 Clinical Trial 6/10/2014
Agios Pharmaceuticals (AGIO) Initiates Multiple Ascending Dose Trial In Healthy Volunteers Of AG-348 For The Potential Treatment Of PK Deficiency, A Rare, Hemolytic Anemia 6/9/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For IMMU-132 For Pancreatic Cancer Therapy 6/9/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-DMPK Rx To Treat Myotonic Dystrophy Type 1 6/9/2014
D-Pharm Ltd.'s Anti-Epileptic Drug DP-VPA Is Granted Fast Track Status By The Chinese Food And Drug Administration (CFDA) 6/9/2014
Genentech (RHHBY) Bladder Cancer Med Anti-PDL1 (MPDL3280A) Nabs Breakthrough Status 6/9/2014
Medgenics, Inc. Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE) 6/6/2014
ImaginAb, Inc. Presents Initial Phase I/Iia Results For Prostate Imaging Agent At Society of Nuclear Medicine And Molecular Imaging (SNMMI) Annual Meeting 6/6/2014
Advaxis, Inc.'s ADXS-Cher2 Immunotherapy Continues To Demonstrate Significantly Prolonged Survival In Canine Osteosarcoma 6/6/2014
Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of LV305 Immuno-Oncology Agent 6/5/2014
Momenta Pharmaceuticals, Inc. (MNTA) Receives Orphan Drug Designation For Necuparanib (Formerly M402) In Pancreatic Cancer 6/5/2014
Curis, Inc. (CRIS) Announces Re-Initiation Of Patient Dosing In CUDC-427 Monotherapy Clinical Trial 6/5/2014
Edge Therapeutics Initiates Enrollment Of Second Cohort In Phase 1/2 NEWTON Study Of EG-1962 For Improvement Of Outcome After Ruptured Brain Aneurysm 6/5/2014
SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data At Epilepsy Pipeline Conference 6/5/2014
Ocugen, Inc. Receives Orphan Designation For OCU100 To Treat Retinitis Pigmentosa 6/5/2014
AstraZeneca PLC (AZN) Shows Off Its Cancer Pipeline 6/4/2014
Kadmon Corporation Announces The Initiation Of A Phase 1b/2a Study Of KD019 And Trastuzumab In HER2-Positive Metastatic Breast Cancer 6/4/2014
Advanced Cancer Therapeutics Enters Phase 1 Human Clinical Trials With First-in-Class Anti-Cancer Drug Candidate 6/4/2014
United Cannabis Corporation Release: FDA Approval Of Medical MJ: Phase I Human Studies Explored By Team Of Experts 6/4/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs At The 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Cerulean Pharma Inc. (CERU) Announces CRLX101 Combination Data At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 1b Clinical Trial Of APD334 For Autoimmune Diseases 6/3/2014
Protalex, Inc. (PRTX) Announces Preliminary Unblinded Findings From Cohorts 1-4 Of U.S. Phase 1b Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 6/3/2014
AstraZeneca PLC (AZN)’s MedImmune (AZN) Presents Encouraging Immunotherapy Data at American Society of Clinical Oncology 2014 6/3/2014
Xcovery Presents Interim Phase 1 Results Of X-396 In ALK Positive NSCLC At The American Society of Clinical Oncology Annual Meeting 6/3/2014
AbbVie (ABBV) Touts Early Phase 1 Success With Brain Cancer Drug 6/2/2014
AbbVie (ABBV) Presents New Results From Studies Of Investigational Oncology Compound ABT-199/GDC-0199 At The 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Longer-Term Safety And Efficacy Data Of Ponatinib From PACE And Phase 1 Clinical Trials 6/2/2014
Data on Merck & Co., Inc. (MRK)’s Pembrolizumab From Largest Study To Date Of Investigational Anti-PD-1 Antibody In Advanced Melanoma Highlighted At American Society of Clinical Oncology 2014 6/2/2014
Karyopharm Therapeutics (KPTI) Updates Data For Selinexor In Solid Tumors At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Seattle Genetics, Inc. (SGEN) Presents Data from Phase 1 Clinical Trial Of Antibody-Drug Conjugate (ADC) SGN-CD19A In Non-Hodgkin Lymphoma At American Society of Clinical Oncology Annual Meeting 6/2/2014
Immunomedics, Inc. (IMMU) Reports IMMU-130 Is Active In Patients With Irinotecan-Refractory Colorectal Cancer 6/2/2014
Ignyta Announces Interim Data From RXDX-101 Phase I Clinical Trial 6/2/2014
AVEO Oncology (AVEO) Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Galena Biopharma  (GALE) Presents GALE-301 Phase 1 Data At The American Society of Clinical Oncology 50th Annual Meeting 6/2/2014
Karyopharm Therapeutics (KPTI) Provides Data Update For Selinexor In Non-Hodgkin's Lymphoma And Acute Myeloid Leukemia At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Clovis Oncology (CLVS) Announces Encouraging Data From Phase 1/2a Study Evaluating Lucitanib In Advanced Solid Tumors 6/2/2014
Clovis Oncology (CLVS)’s CO-1686 Demonstrates Compelling Clinical Activity And Progression-Free Survival (PFS) In Updated Phase 1/2 Study Results In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 6/2/2014
Clovis Oncology (CLVS)’s Phase 1 Study Of Rucaparib Demonstrates Compelling Clinical Activity and Safety In Patients With Solid Tumors 6/2/2014
Immunomedics, Inc. (IMMU) Reports Final Efficacy Results Of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan In Patients With Metastatic Pancreatic Cancer 6/2/2014
Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study 6/2/2014
Nanobiotix Presents Successful Phase I Results For Its Lead Nanomedicine Product NBTXR3 At American Society of Clinical Oncology 6/2/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Positive Updated Results From Ongoing MD Anderson Cancer Center-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS At American Society of Clinical Oncology 2014 Annual Meeting 6/2/2014
Verastem, Inc. (VSTM) Presents Updated Clinical Data From VS-6063 And Paclitaxel Combination Phase 1/1b Study In Patients With Ovarian Cancer At The 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Scancell: Update On Phase 1/2 Clinical Trial Of SCIB1 In Stage III/IV Melanoma 6/2/2014
Aduro Biotech Announces American Society of Clinical Oncology Presentation Of Promising Results From Phase 1b Clinical Trial Of Its Novel Immunotherapy For The Treatment Of Mesothelioma 6/2/2014
HealthCare Pharmaceuticals Announces American Society of Clinical Oncology Presentation Of DKN-01 Clinical Study In Non-Small Cell Lung Cancer And First Patients Dosed In Clinical Study For DKK1+ Esophageal Cancer 6/2/2014
Deciphera Pharmaceuticals Announces Initiation Of Phase 1 Cancer Trial For Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor For Solid Tumors 5/30/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma 5/30/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Bevacizumab (Avastin®) In Patients With Recurrent Glioblastoma 5/30/2014
Heat Biologics Receives Green Light To Expand Enrollment Of Its Phase 1/2 Study Of HS-410 In Bladder Cancer Based On Encouraging Preliminary Safety Results 5/30/2014
Dilaforette Presents Results From Exploratory Phase 1/2 Clinical Trial In Uncomplicated Malaria 5/30/2014
Benitec Limited (BLT.AX) Commences Patient Dosing With TT-034 In Patients With Hepatitis C 5/29/2014
Symphogen A/S To Report Preliminary Safety And Exploratory Efficacy Data From A Phase 1 Study Of Sym004, Anti-EGFR Monoclonal Antibody Mixture At American Society of Clinical Oncology 5/29/2014
Dyax Corp. (DYAX) Announces Dosing Of First Subject In Phase 1b Trial Of DX-2930 In Patients With Hereditary Angioedema 5/28/2014
Xencor Initiates Phase 1 Study Of XmAb7195 For Asthma 5/28/2014
AtheroNova Inc. (AHRO.OB) Announces Russian Ministry Of Healthcare Approval For Initiation Of Phase 1b Trial Investigating AHRO-001 5/28/2014
Biocryst Pharmaceuticals (BCRX) To Announce Results From The BCX4161 Opus-1 Phase 2 Trial For Hereditary Angioedema May 27 5/27/2014
Tekmira Pharmaceuticals Corporation Initiating Phase1/2 Clinical Trial In Patients With Hepatocellular Carcinoma 5/27/2014
uniQure Announces Successful Transfection Of Liver Cells With AAV5 And Strong Safety Data From Acute Intermittent Porphyria Clinical Trial 5/27/2014
Immune Design Corporation's GLAAS™ Discovery Platform Used In MEDI7510 Phase 1 Trial For Respiratory Syncytial Virus 5/27/2014
Northwest Biotherapeutics (NWBO) Release: Early Positive Responses Seen In Over 50% Of Dcvax®-Direct Patients To Date 5/27/2014
Depymed Announces Validation Of Trodusquemine As A Therapeutic Candidate For HER2-Positive Breast Cancer 5/27/2014
Tekmira Pharmaceuticals Corporation Presents Positive Interim Results on Phase 1/2 Clinical Programs 5/22/2014
Anavex Life Sciences Corp. (AVXL.OB) Reports That New Data Confirms Calcium Target Over-Expression May Be Involved In Causing Alzheimer's Disease 5/22/2014
StemCells Inc. (STEM) Advances Clinical Trial In Age-Related Macular Degeneration To Final Cohort 5/22/2014
Zalicus Inc. (ZLCS) Updates Progress On Z944 Clinical Development 5/22/2014
Amgen (AMGN) Release: The New England Journal of Medicine Publishes Positive Proof-Of-Concept Data For New Asthma Treatment 5/21/2014
Immunomedics, Inc. (IMMU) Reports Results With IMMU-132 In Patients With Pancreatic Cancer 5/21/2014
aTyr Pharma Inc. Completes First Phase 1 Study For Rare Disease Program 5/21/2014
Galena Biopharma  (GALE) To Present GALE-301 Phase 1 Data At The American Society of Clinical Oncology 50th Annual Meeting 5/21/2014
Clovis Oncology (CLVS) Wins Breakthrough Status For Lung Cancer Candidate CO-1686 5/21/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-PKK Rx 5/20/2014
Immunomedics, Inc. (IMMU) Reports Results With IMMU-132 In Patients With Pancreatic Cancer 5/20/2014